Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Oisin Biotechnologies
AddedFeb 15, 2024
UpdatedJun 18, 2026
Oisin Biotechnologies

Oisin Biotechnologies

Seed

Oisin Biotechnologies: Innovating precise DNA-targeted drugs to combat age-related diseases.

HQ
Seattle, WA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Oisin Biotechnologies, founded with the mission to combat age-related diseases, is a platform drug development company focused on creating precise, DNA-targeted interventions. Their core vision is to extend healthy human lifespan by developing innovative therapies that clear senescent cells, which are known to contribute to aging and various chronic diseases. The company leverages a patent-pending technology to target and eliminate these harmful cells, aiming to revolutionize the treatment of age-related conditions and improve overall longevity.

Notable figures associated with Oisin Biotechnologies include experts in biotechnology and aging research, though specific names are not provided. The company has attracted significant interest and investment from those passionate about longevity science. Key achievements include the development of their proprietary DNA-targeted intervention platform and promising preclinical results demonstrating the potential of their therapies. Oisin Biotechnologies' work has the potential to significantly impact the field of gerontology and age-related disease treatment, positioning them as a leader in longevity medicine.

Oisin Biotechnologies - Quick Facts

When was Oisin Biotechnologies founded?

Oisin Biotechnologies was founded in 2014.

Where is Oisin Biotechnologies' headquarters located?

Oisin Biotechnologies' headquarters is located in Seattle, WA, US.

When was Oisin Biotechnologies' last funding round?

Oisin Biotechnologies' most recent funding round was for $5M (USD) in May 2021.

How much has Oisin Biotechnologies raised to-date?

As of May 27, 2021, Oisin Biotechnologies has raised a total of $7.1M (USD).

How many employees does Oisin Biotechnologies have?

Oisin Biotechnologies has 18 employees as of Feb 5, 2024.

Oisin Biotechnologies - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Development
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified